A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma.
暂无分享,去创建一个
David M. Thomas | Dina Halai | Sean Davis | Irene L Andrulis | Stephen J Chanock | Roberto Tirabosco | Robert N Hoover | Julie M Gastier-Foster | Neil E Caporaso | Nathan Pankratz | Natalie K. Wolf | Madison T. Weg | Meredith Yeager | Sholom Wacholder | Piero Picci | Paul S Meltzer | Lisa Mirabello | Mitchell J Machiela | Sharon A Savage | Richard Gorlick | P. Meltzer | S. Chanock | R. Hoover | S. Davis | D. Largaespada | J. Gastier-Foster | M. Yeager | S. Wacholder | Zhaoming Wang | M. Tucker | J. Fraumeni | L. Burdett | J. Wunder | I. Andrulis | L. Mirabello | S. Savage | J. Boland | A. Flanagan | P. Picci | A. Patiño-García | F. Lecanda | B. Moriarity | L. Helman | L. Sierrasesúmaga | N. Pankratz | A. Petrilli | K. Scotlandi | M. Ballinger | M. Machiela | N. Caporaso | O. Panagiotou | B. Hicks | C. Khanna | C. Hattinger | M. Serra | R. Koster | R. Tirabosco | R. Gorlick | M. F. Amary | N. Marina | D. Barkauskas | A. Vogt | G. M. Otto | D. Halai | Zhaoming Wang | Joseph F Fraumeni | Donald A Barkauskas | Neyssa Marina | Margaret Tucker | Chand Khanna | L. Spector | Jay S Wunder | Laurie Burdett | Massimo Serra | N. Gokgoz | Ana Patiño-Garcia | Katia Scotlandi | Antonio S Petrilli | Belynda D Hicks | Logan G Spector | Orestis A Panagiotou | Maria Fernanda Amary | Adrienne M Flanagan | Nalan Gokgoz | Claudia Hattinger | Fernando Lecanda | Luis Sierrasesúmaga | Roelof Koster | David M Thomas | Mandy L Ballinger | Lee Helman | David Largaespada | Branden S Moriarity | Joy Gary | Silvia Regina Caminada de Toledo | George M Otto | Kelsie L Becklin | Natalie K Wolf | Madison T Weg | Joseph F Boland | Aurelie Vogt | S. D. de Toledo | J. Gary | L. Sierrasesúmaga | Joy M. Gary
[1] Mitchell J. Machiela,et al. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants , 2015, Bioinform..
[2] Natalie K. Wolf,et al. A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis , 2015, Nature Genetics.
[3] B. Fuchs,et al. Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray. , 2014, Anticancer research.
[4] Ling Guo,et al. miR-365 Promotes Cutaneous Squamous Cell Carcinoma (CSCC) through Targeting Nuclear Factor I/B (NFIB) , 2014, PloS one.
[5] R. Eeles,et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease , 2014, British Journal of Cancer.
[6] T. He,et al. IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma. , 2013, Cancer letters.
[7] J. Buckwalter,et al. Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. , 2013, The Journal of bone and joint surgery. American volume.
[8] David M. Thomas,et al. Genome-wide Association Study Identifies Two Susceptibility Loci for Osteosarcoma , 2013, Nature Genetics.
[9] Anne-Marie Cleton-Jansen,et al. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma , 2013, BMC Cancer.
[10] Bernat Gel,et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and genetic pathways driving tumorigenesis , 2013, Nature Genetics.
[11] R. Eeles,et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Knuutila,et al. MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone. , 2013, Histology and histopathology.
[13] Data production leads,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .
[14] Eurie L. Hong,et al. Annotation of functional variation in personal genomes using RegulomeDB , 2012, Genome research.
[15] Daniel Birnbaum,et al. 8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer , 2012, PloS one.
[16] J. Shand,et al. IGFBP5 induces cell adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells , 2012, Journal of Cell Science.
[17] B. Qian,et al. Increased expression of insulin‐like growth factor‐1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma , 2012, Journal of surgical oncology.
[18] Manolis Kellis,et al. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants , 2011, Nucleic Acids Res..
[19] S. Savage,et al. Case-parent analysis of variation in pubertal hormone genes and pediatric osteosarcoma: a Children's Oncology Group (COG) study. , 2012, International journal of molecular epidemiology and genetics.
[20] Nilanjan Chatterjee,et al. Improved imputation of common and uncommon SNPs with a new reference set , 2011, Nature Genetics.
[21] Wonshik Han,et al. NFIB is a potential target for estrogen receptor‐negative breast cancers , 2011, Molecular oncology.
[22] A. Temme,et al. Silencing of selected glutamate receptor subunits modulates cancer growth. , 2011, Anticancer research.
[23] J. Qin,et al. Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma , 2011, Oncogene.
[24] T. Scheetz,et al. Novel Molecular and Computational Methods Improve the Accuracy of Insertion Site Analysis in Sleeping Beauty-Induced Tumors , 2011, PloS one.
[25] Jai-Sing Yang,et al. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor. , 2011, International journal of oncology.
[26] Levi Garraway,et al. Nuclear factor I/B is an oncogene in small cell lung cancer. , 2011, Genes & development.
[27] R. Hoover,et al. Height at diagnosis and birth-weight as risk factors for osteosarcoma , 2011, Cancer Causes & Control.
[28] L. Mirabello,et al. Using Epidemiology and Genomics to Understand Osteosarcoma Etiology , 2011, Sarcoma.
[29] D. Altshuler,et al. A map of human genome variation from population-scale sequencing , 2010, Nature.
[30] R. Weber,et al. Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance , 2010, Clinical Cancer Research.
[31] H. Horlings,et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.
[32] F. Pedeutour,et al. HMGA2-NFIB fusion in a pediatric intramuscular lipoma: a novel case of NFIB alteration in a large deep-seated adipocytic tumor. , 2009, Cancer genetics and cytogenetics.
[33] D. Campanacci,et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. , 2009, European journal of cancer.
[34] Lisa Mirabello,et al. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons , 2009, International journal of cancer.
[35] W. Rzeski,et al. Expression of glutamate receptor subunits in human cancers , 2009, Histochemistry and Cell Biology.
[36] D. Leroith,et al. Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin‐like growth factor I , 2009, International journal of cancer.
[37] L. Mirabello,et al. Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.
[38] Xiaoying Wang,et al. Nuclear factor I transcription factors regulate IGF binding protein 5 gene transcription in human osteoblasts. , 2009, Biochimica et biophysica acta.
[39] A. Italiano,et al. NFIB rearrangement in superficial, retroperitoneal, and colonic lipomas with aberrations involving chromosome band 9p22 , 2008, Genes, chromosomes & cancer.
[40] Shuji Fujita,et al. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. , 2008, Journal of molecular biology.
[41] C. Conover. Insulin-like growth factor-binding proteins and bone metabolism. , 2008, American journal of physiology. Endocrinology and metabolism.
[42] P. Donnelly,et al. A new multipoint method for genome-wide association studies by imputation of genotypes , 2007, Nature Genetics.
[43] D. Reich,et al. Population Structure and Eigenanalysis , 2006, PLoS genetics.
[44] D. Pérol,et al. Metastatic osteosarcoma at diagnosis , 2005, Cancer.
[45] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[46] W. Winkelmann,et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] H. Tsuchiya,et al. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] S. Steinberg,et al. Treatment of Metastatic Osteosarcoma With the Somatostatin Analog OncoLar: Significant Reduction of Insulin-Like Growth Factor-1 Serum Levels , 2002, Journal of pediatric hematology/oncology.
[49] A. Hoeflich,et al. IGF-binding protein-5: flexible player in the IGF system and effector on its own. , 2002, The Journal of endocrinology.
[50] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] A. Hoeflich,et al. Insulin-like growth factor-binding protein-5 inhibits growth and induces differentiation of mouse osteosarcoma cells. , 2001, Biochemical and biophysical research communications.
[53] R. Gronostajski,et al. Roles of the NFI/CTF gene family in transcription and development. , 2000, Gene.
[54] W. Kiess,et al. Insulin-like growth factor-I inhibits the progression of human U-2 OS osteosarcoma cells towards programmed cell death through interaction with the IGF-I receptor. , 2000, Cellular and molecular biology.
[55] I. Andrulis,et al. Expression of insulin‐like growth factor receptor, IGF‐1, and IGF‐2 in primary and metastatic osteosarcoma , 1998, Journal of surgical oncology.
[56] R W Blamey,et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. , 1995, Human pathology.
[57] S. Hirschfeld,et al. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. , 1994, Cancer research.
[58] C. Conover,et al. Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells. , 1993, The Journal of clinical endocrinology and metabolism.
[59] A. Huvos,et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Dean Hamer,et al. ETIOLOGY , 1931 .